[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Addpharma Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":428},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,42,62,84,102,119,138,161,179,200,221,236,256,274,293,310,331,350,371,392,411],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638873","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-safety-and-food-effect-of-ad-230-in-healthy-adults-100638873",false,"NCT07618845","A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults","A Randomized, Open-label, 2-period, 2-sequence, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of AD-230 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults",[28],"Chronic Liver Disease (CLD)","NOT_YET_RECRUITING","2026-05-26",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":22},"2026-05",{"date":37,"type":22},"2026-07",{"name":39,"class":40},"Addpharma Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":46,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":41},"100639685","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-231-compared-to-coadministration-of-ad-231a-ad-231d-and-ad-231c-100639685","NCT07590167","A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":50,"type":22},60,[25],[53,54],"Dyslipidemia","Hypertension","2026-05-11",{"date":57,"type":33},"2026-05-15",{"date":59,"type":22},"2026-06",{"date":37,"type":22},{"name":39,"class":40},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100635249","phase-2-determining-the-optimal-dose-of-ad-211-in-patients-with-osteoarthritis-of-the-knee-100635249","NCT07550231","Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with osteoarthritis of the Knee\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with secondary osteoarthritis of the knee\n* Other exclusions applied","75 Years",{"count":71,"type":22},200,[73],"PHASE2","The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.",[76],"Osteoarthritis of the Knees","2026-04-20",{"date":79,"type":33},"2026-04-24",{"date":59,"type":22},{"date":82,"type":22},"2027-03",{"name":39,"class":40},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":88,"conditions":94,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":41},"100634344","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-123-compared-to-coadministration-of-ad-1231-and-ad-1232-100634344","NCT07538466","A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Adult Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":92,"type":22},50,[25],[95],"Diabetes Mellitus","2026-04-12",{"date":77,"type":33},{"date":99,"type":22},"2026-04",{"date":35,"type":22},{"name":39,"class":40},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":106,"conditions":112,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":118,"locationsCount":41},"100633019","phase-1-a-clinical-trial-to-evaluate-the-pharmacokinetics-and-safety-of-ad-230-in-healthy-adults-100633019","NCT07521241","A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","A Randomized, Open-label, Two-treatment, Two-period, Two-sequence Crossover Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults","Inclusion Criteria:\n\n* \\- Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":110,"type":22},52,[25],[28],"2026-04-08",{"date":115,"type":33},"2026-04-13",{"date":35,"type":22},{"date":37,"type":22},{"name":39,"class":40},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":137,"locationsCount":41},"100629552","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-118-and-ad-1181-in-healthy-adult-subjects-100629552","NCT07476157","A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":127,"type":22},70,[25],"A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects",[131],"Chronic Heart Failure","2026-03-12",{"date":134,"type":33},"2026-03-17",{"date":99,"type":22},{"date":35,"type":22},{"name":39,"class":40},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":16,"sex":145,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":41},"100627111","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-116-and-ad-1161-in-healthy-adult-male-subjects-100627111","NCT07444385","A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects","An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied","MALE",{"count":147,"type":22},44,[25],"A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects",[151],"Benign Prostatic Hyperplasia","RECRUITING","2026-03-01",{"date":155,"type":33},"2026-03-03",{"date":157,"type":33},"2026-02-26",{"date":159,"type":22},"2026-05-08",{"name":39,"class":40},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":178,"locationsCount":4},"100622563","phase-1-a-clinical-trial-to-assess-the-pharmacokinetics-and-safety-of-ad-229-compared-to-ad-2291-in-healthy-adults-100622563","NCT07385248","A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults","An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":169,"type":22},28,[25],"The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-229 and the administration of AD-2291 in healthy adults.",[173],"Gastritis",{"date":175,"type":33},"2026-02-27",{"date":99,"type":22},{"date":59,"type":22},{"name":39,"class":40},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":41},"100622562","phase-1-compare-and-evaluate-the-safety-and-pk-data-of-a-single-dose-administration-of-ad-115a-or-ad-1151-100622562","NCT07385235","Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'","A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State","Inclusion Criteria:\n\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n\nExclusion Criteria:\n\n* Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day)\n* Other exclusions applied",{"count":187,"type":22},46,[25],"The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.",[191],"Gastric Ulcer","2026-02-09",{"date":194,"type":33},"2026-02-11",{"date":196,"type":33},"2026-01-27",{"date":198,"type":22},"2026-03-16",{"name":39,"class":40},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":41},"100616988","phase-1-a-study-to-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-231a-and-ad-231b-and-ad-231c-100616988","NCT07312773","A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥19 and \\\u003C65 years at the time of the screening visit\n* Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg\u002Fm² and 30.0 kg\u002Fm² at the time of the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":208,"type":22},55,[25],"To evaluate the pharmacokinetic interactions of AD-231A, AD-231B, and AD-231C in healthy adult volunteers.",[54,212],"Hyperlipidemia","2025-12-17",{"date":215,"type":33},"2025-12-31",{"date":217,"type":22},"2026-01-23",{"date":219,"type":22},"2026-02-22",{"name":39,"class":40},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":235,"locationsCount":41},"100616990","phase-1-evaluate-the-pharmacokinetic-interaction-and-the-safety-of-ad-2321-and-ad-2322-100616990","NCT07312799","Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322","A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers",{"count":228,"type":22},41,[25],"To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.",[54],{"date":215,"type":33},{"date":196,"type":22},{"date":157,"type":22},{"name":39,"class":40},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":41},"100604696","phase-1-a-study-to-compare-to-pk-characteristics-and-safety-profiles-between-ad-117-and-ad-117a-100604696","NCT07152873","A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":50,"type":22},[25],"Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.",[247],"Mixed Dyslipidemia","2025-11-27",{"date":250,"type":33},"2025-12-04",{"date":252,"type":22},"2025-12-01",{"date":254,"type":22},"2026-03",{"name":39,"class":40},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":16,"sex":145,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":4},"100600883","phase-1-a-clinical-trial-to-evaluate-the-safety-and-the-pharmacokinetics-of-ad-116-compared-to-ad-1161-in-healthy-adult-male-volunteers-100600883","NCT07103278","A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions",{"count":147,"type":22},[25],"The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers",[151],"2025-09-30",{"date":268,"type":33},"2025-10-03",{"date":270,"type":22},"2025-12",{"date":272,"type":22},"2026-01",{"name":39,"class":40},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":41},"100591135","phase-1-the-food-effect-on-pk-characteristics-and-safety-profiles-of-pa-111-100591135","NCT06976489","The Food Effect on PK Characteristics and Safety Profiles of PA-111","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Food Effect on the Safety and the Pharmacokinetics of PA-111 in Healthy Adult Volunteers",{"count":281,"type":22},40,[25],"Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.",[247],"2025-05-09",{"date":287,"type":33},"2025-05-16",{"date":289,"type":22},"2025-05",{"date":291,"type":22},"2025-07",{"name":39,"class":40},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":283,"conditions":302,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":41},"100587770","phase-1-a-study-to-compare-to-pk-characteristics-and-safety-profiles-between-pa-111-and-pa-111a-100587770","NCT06932705","A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of PA-111 Compared to PA-111A in Healthy Adult Volunteers Under Fed State Conditions",{"count":300,"type":22},48,[25],[247],"2025-04-10",{"date":305,"type":33},"2025-04-17",{"date":307,"type":22},"2025-04",{"date":289,"type":22},{"name":39,"class":40},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":41},"100586496","phase-1-a-study-to-compare-pkpd-characteristics-and-safety-profiles-between-ad-120-and-ad-120a-100586496","NCT06916130","A Study to Compare PK\u002FPD Characteristics and Safety Profiles Between AD-120 and AD-120A","A Randomized, Open-label, Multiple Oral-dose, 2x2 Crossover Clinical Trial to Compare the Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a AD-120 and AD-120A in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50.0kg and equal to or less than 90.0kg and Body mass index (BMI) between 18.5 kg\u002Fm2 and 29.9 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 and equal to or less than 50 in healthy volunteers at the time of screening visit\n* Negative result from Serum Helicobacter pylori antibody at the time of screening visit\n\nExclusion Criteria:\n\n* Patients with trouble performing pH monitor catheter","50 Years",{"count":300,"type":22},[25],"Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.",[322],"Gastroesophageal Reflux Disease (GERD)","2025-03-31",{"date":325,"type":33},"2025-04-08",{"date":327,"type":22},"2025-04-21",{"date":329,"type":22},"2025-09-01",{"name":39,"class":40},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":41},"100584035","phase-1-a-study-to-compare-pk-characteristics-and-safety-profiles-between-ad-228b-and-ad-2284-100584035","NCT06884098","A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",{"count":50,"type":22},[25],"Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.",[342],"Primary Hypercholesterolaemia","2025-03-18",{"date":345,"type":33},"2025-03-20",{"date":347,"type":33},"2025-03-10",{"date":307,"type":22},{"name":39,"class":40},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":41},"100470014","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-218-100470014","NCT05400317","A Study to Evaluate the Efficacy and Safety of AD-218","A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients with Mixed Dyslipidemia","Inclusion Criteria:\n\n* A man or woman over 19 years old.\n* Sign on ICF prior to study participation\n\nExclusion Criteria:\n\n* History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)\n* Other exclusions applied",{"count":358,"type":22},520,[360],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of AD-218",[247],"2025-02-03",{"date":365,"type":33},"2025-02-05",{"date":367,"type":33},"2022-07-27",{"date":369,"type":22},"2026-06-30",{"name":39,"class":40},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100573565","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-co-administration-of-ad-2281-and-ad-2282-100573565","NCT06747936","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282","A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Primary Hypercholesterolemia\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with Secondary Hypercholesterolemia\n* Other exclusions applied",{"count":379,"type":22},110,[360],"The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia",[383],"Primary Hypercholesterolemia","2025-02-02",{"date":386,"type":33},"2025-02-04",{"date":388,"type":22},"2025-02",{"date":390,"type":22},"2026-12",{"name":39,"class":40},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":41},"100550020","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-co-administration-of-ad-227a-and-ad-227b-100550020","NCT06441630","A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B","A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Essential Hypertension\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patient with Secondary Hypertension\n* Other exclusions applied",{"count":400,"type":22},251,[360],"The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension",[404],"Essential Hypertension",{"date":386,"type":33},{"date":407,"type":33},"2024-07-31",{"date":409,"type":22},"2025-09",{"name":39,"class":40},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":41},"100538466","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-224-100538466","NCT06291207","A Study to Evaluate the Efficacy and Safety of AD-224","A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension",{"count":418,"type":22},252,[360],"The purpose of this study is to evaluate the efficacy and safety of AD-224",[422],"Hypertension,Essential",{"date":386,"type":33},{"date":425,"type":33},"2024-04-15",{"date":291,"type":22},{"name":39,"class":40},""]